Navigation Links
Heart Imaging Technologies Wins $2.5M NIH Grant for Clinical Trials
Date:9/4/2013

DURHAM, N.C., Sept. 4, 2013 /PRNewswire/ -- HeartIT, the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the NIH in order to develop the "Cloud Based Corelab of the Future."

Medical drugs and devices are regulated by the U.S. Food and Drug Administration (FDA) based on data from multicenter clinical trials. Over the past decade the efficiency of clinical trials has been improved by electronic data capture (EDC) systems, whose use has increased from 38% to 61% from 2006 to 2011. While medical imaging plays a key role in clinical trials, often serving as the basis for study end-points and/or safety evaluations, few if any EDC systems integrate imaging corelab workflows such as image quality assurance, site queries, and reporting of end-point analyses.

The overall goal of the NIH grant is to create a "cloud-based imaging corelab of the future" that provides support for all imaging corelab activities and integration into EDCs.

HeartIT is already a leader in the Clinical Trials market ( http://www.heartit.com/index.php/solutions ), and received an additional $2.25M NIH grant in 2011 ( http://www.heartit.com/index.php/2011/11 ).

Dr. Robert M. Judd, President of HeartIT stated: "Heart Imaging Technologies developed the world's first "zero footprint" medical image viewer, WebPAX®, which displays diagnostic-quality images in a bare bones web browser. We are the natural choice for this type of project. By moving imaging corelabs out of their traditional 'brick-and-mortar' environments and into the 'cloud,' medical images can be interpreted from anywhere in the world within minutes rather than weeks."

Judd added, "Moving corelabs to 'the cloud' will not only improve corelab workflows, but will also improve communication between the corelab and the other clinical trials stakeholders such as the CRO, the data safety and monitoring board (DSMB), the sponsor, and the FDA. In addition, making images available rapidly will enable new trial designs that reduce site-to-site variability of the study population, thereby reducing the number of patients needed to detect treatment effects, trial durations, and trial costs."

About Heart IT:

Founded in 2000 and headquartered near North Carolina's Research Triangle Park, Heart IT is a global leader in the medical image web enablement field. Their flagship product, WebPAX®, is the first FDA approved zero foot-print medical image workstation. It provides web-based medical image management technology and services to health care systems, large hospitals and private clinics as well as drug and device companies sponsoring multi-center clinical trials. Worldwide, WebPAX® systems currently provide secure web browser access to over one billion medical images. For more information visit our website at www.heartit.com.

This release was issued through Send2Press(R), a unit of Neotrope(R). For more information, visit Send2Press Press Release Distribution at http://www.Send2Press.com


'/>"/>
SOURCE Heart Imaging Technologies
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York
3. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
4. Remedy Informatics Cardiovascular Registry Selected by World-Renowned Cleveland Clinic Heart and Vascular Institute
5. Heartware Schedules First Quarter Conference Call And Webcast
6. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
7. Stereotaxis Epoch™ Solutions Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting
8. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
9. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
10. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
11. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):